While incomplete RFA (iRFA) in HCC risks triggering aggressive recurrence through proliferative and angiogenic pathways (often mitigated by adjuncts such as metformin, hydroxychloroquine, sorafenib, bevacizumab, CTLA-4 inhibitors, or interferon-α that may help mitigate these effects [19]), pancreatic tumors demand more nuanced approaches. The gene discussed is CTLA4; the disease is pancreatic neoplasm.